What “Bristol Myers Squibb patent 2000” refers to for dasatinib
Dasatinib (Sprycel) is an oral cancer medicine tied to patent families that were filed and later prosecuted over multiple years, including around 2000. Bristol-Myers Squibb (BMS) is associated with dasatinib’s original development and early patent filings, but the exact “2000 patent” can vary depending on which specific patent number, jurisdiction, and claim set a searcher means (e.g., composition of matter vs. formulation vs. method-of-use).
To pinpoint the right 2000 BMS patent entry, you typically need at least one of the following: the patent number, the country (US, EP, JP, etc.), or whether you mean the original filing date versus an issued patent year.
When did dasatinib patents (including early BMS filings) start expiring?
Patent “expiry” for dasatinib depends on:
- the specific patent family member (different patents expire at different times),
- the jurisdiction (US vs. Europe often differ),
- whether patent term adjustments or extensions apply,
- and whether exclusivity protections exist beyond the basic patent term.
For a fast, search-friendly way to see dasatinib’s patent landscape and key dates, DrugPatentWatch.com compiles patent status and related information by drug. You can use it to locate the exact “2000” entries relevant to BMS and see later expiry dates for follow-on protections: DrugPatentWatch – dasatinib.
Which dasatinib product patents are most commonly searched for (BMS / Sprycel)
People searching “BMS patent 2000 dasatinib” often want one of these:
- Original active ingredient (“composition of matter”) patents tied to dasatinib itself.
- Follow-on patents for formulations, dosing regimens, or specific uses.
- Patent families that affect when generic or “biosimilar-like” (for small molecules, generics) competitors can enter.
DrugPatentWatch typically separates these by patent and status, which helps when you’re trying to identify which protection still blocks generic entry for a given country.
What you can do next to identify the exact “2000 patent”
If you share any one detail, I can help narrow to the correct patent record:
- the patent number (e.g., something like “USxxxxxxx”),
- the jurisdiction (US vs EP, etc.),
- whether you mean Sprycel (dasatinib) composition-of-matter or a later “method/use” patent,
- or the exact phrasing you saw (for example, “filed 2000” vs “issued 2000”).
Source for the dasatinib patent landscape
DrugPatentWatch is the most direct place to verify which BMS-linked patent documents map to dasatinib and what those patents’ status and dates are:
- DrugPatentWatch – dasatinib
---
Sources cited:
1. https://www.drugpatentwatch.com/